import type { Metadata } from "next";
import ClinicalArticleLayout from "@/components/ClinicalArticleLayout";
import Link from "next/link";

export const metadata: Metadata = {
  title: { absolute: "ApoB Blood Test UK Private Apolipoprotein B Testing | Veridian Clinic" },
  description:
    "A private ApoB blood test in the UK measures the number of atherogenic lipoprotein particles in your blood a more accurate cardiovascular risk marker than LDL cholesterol, especially in metabolic syndrome and insulin resistance. Included in the Metabolic Baseline (£595) and Longevity Panel (£795).",
  alternates: {
    canonical: "https://veridianclinic.com/blood-tests/apob",
  },
  openGraph: {
    title: "ApoB Blood Test UK Private Apolipoprotein B Testing | Veridian Clinic",
    description:
      "Private ApoB testing in the UK. Apolipoprotein B measures atherogenic particle count a direct, actionable handle on cardiovascular risk that standard NHS lipid panels miss.",
    url: "https://veridianclinic.com/blood-tests/apob",
    type: "article",
  },
  keywords: [
    "ApoB test UK private",
    "apolipoprotein B blood test UK",
    "ApoB cardiovascular risk UK",
    "private lipid panel UK",
    "ApoB vs LDL UK",
    "atherogenic particle count UK",
    "advanced cholesterol test UK",
    "ApoB insulin resistance",
    "apolipoprotein B normal range UK",
    "metabolic blood test UK",
    "cardiovascular risk markers UK",
    "ApoB longevity UK",
  ],
};

const paragraph = { fontSize: ".96rem", color: "var(--sl2)", lineHeight: 1.95 } as const;
const sectionHeading = { fontSize: "2rem", fontWeight: 500, color: "var(--sl)" } as const;
const callout = { padding: "18px 20px", background: "var(--iv)", borderLeft: "3px solid var(--go)" } as const;

const schema = {
  "@context": "https://schema.org",
  "@type": "Article",
  headline: "ApoB Blood Test UK Private Apolipoprotein B Testing",
  description:
    "A private ApoB blood test in the UK measures atherogenic lipoprotein particle count a more accurate cardiovascular risk marker than LDL-C, especially in insulin resistance and metabolic syndrome.",
  author: { "@type": "Person", name: "Dr Oluwatosin Taiwo", url: "https://veridianclinic.com" },
  publisher: {
    "@type": "Organization",
    name: "Veridian Clinic",
    url: "https://veridianclinic.com",
    logo: { "@type": "ImageObject", url: "https://veridianclinic.com/og-image.jpg" },
  },
  datePublished: "2026-05-11",
  dateModified: "2026-05-11",
  mainEntityOfPage: { "@type": "WebPage", "@id": "https://veridianclinic.com/blood-tests/apob" },
  image: "https://veridianclinic.com/og-image.jpg",
};

export default function ApoBTestPage() {
  return (
    <>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{ __html: JSON.stringify(schema) }}
      />
      <ClinicalArticleLayout
        eyebrow="Private Blood Tests UK"
        title="ApoB blood test UK what apolipoprotein B measures and why it matters more than LDL"
        intro="Most UK NHS cholesterol panels measure LDL-C the amount of cholesterol carried inside low-density lipoprotein particles. ApoB measures something more fundamental: the number of atherogenic lipoprotein particles circulating in your bloodstream. That distinction changes how cardiovascular risk should be assessed, especially in people with insulin resistance, elevated triglycerides, or metabolic syndrome."
        ctas={[
          { href: "/book?tier=baseline", label: "Book Metabolic Baseline ApoB included £595 →" },
          { href: "/metabolic-quiz", label: "Check Your Metabolic Age Free →", variant: "secondary" },
        ]}
      >
        <p style={paragraph}>
          ApoB (apolipoprotein B) is a structural protein present on every major atherogenic lipoprotein including VLDL, IDL, LDL, and lipoprotein(a). Because each atherogenic particle carries exactly one ApoB molecule, measuring ApoB gives a direct count of the particles capable of penetrating the arterial wall and initiating the plaque-formation cascade. This is why a private ApoB blood test in the UK has become a cornerstone of advanced cardiovascular risk assessment.
        </p>

        <div style={callout}>
          <p style={{ fontSize: ".88rem", color: "var(--sl2)", lineHeight: 1.8 }}>
            <strong style={{ color: "var(--fo)" }}>Clinical bottom line:</strong> ApoB reflects particle count. LDL-C reflects cholesterol mass. When the two diverge which is common in metabolic syndrome and insulin resistance ApoB is usually the more reliable predictor of cardiovascular risk.
          </p>
        </div>

        <h2 className="cg" style={sectionHeading}>What does an ApoB test measure?</h2>
        <p style={paragraph}>
          An ApoB blood test measures the concentration of apolipoprotein B-100 in the blood, expressed in grams per litre (g/L). Because every VLDL, IDL, LDL, and Lp(a) particle carries one ApoB-100 molecule, the result directly reflects the total number of atherogenic particles circulating in your system. A higher ApoB means more particles capable of crossing the endothelial barrier, becoming retained in the arterial wall, and driving the inflammatory process that creates atherosclerotic plaque.
        </p>
        <p style={paragraph}>
          Standard NHS lipid panels measure LDL cholesterol (LDL-C), which estimates the cholesterol content carried inside LDL particles. This distinction is clinically important because two people can have the same LDL-C yet very different ApoB values if they carry different numbers of particles. A person with small, cholesterol-depleted LDL particles will have a lower LDL-C per particle their LDL-C may look acceptable while their particle count remains high. Their ApoB captures the reality that their cholesterol panel obscures.
        </p>

        <h2 className="cg" style={sectionHeading}>Why ApoB is a better cardiovascular risk marker than LDL in metabolic dysfunction</h2>
        <p style={paragraph}>
          The gap between ApoB and LDL-C is most pronounced in individuals with insulin resistance, elevated triglycerides, central obesity, or mixed dyslipidaemia. In these patients, the liver tends to produce a larger number of smaller, triglyceride-rich VLDL particles. As these are processed by lipoprotein lipase, they yield smaller, denser LDL particles that carry less cholesterol per particle but remain fully atherogenic. The result: elevated ApoB with a deceptively modest LDL-C.
        </p>
        <p style={paragraph}>
          This is known as LDL discordance, and it is one of the key reasons that relying solely on LDL-C in a metabolically unhealthy population can underestimate cardiovascular risk. Studies across preventive cardiology consistently show that ApoB and LDL particle number add meaningful risk stratification beyond LDL-C, particularly in patients with the atherogenic dyslipidaemia phenotype common to metabolic syndrome.
        </p>
        <ul className="chk">
          <li>Elevated ApoB with normal-to-borderline LDL-C is a recognised high-risk pattern in metabolic syndrome.</li>
          <li>ApoB captures risk from all atherogenic particles not just LDL, but also VLDL remnants and Lp(a).</li>
          <li>Reducing ApoB is a measurable, trackable treatment target in preventive cardiology.</li>
          <li>ApoB is particularly informative when combined with fasting insulin, triglycerides, and Lp(a).</li>
        </ul>

        <h2 className="cg" style={sectionHeading}>What are optimal ApoB levels?</h2>
        <p style={paragraph}>
          Laboratory reference ranges in the UK typically quote ApoB as normal below 1.2-1.3 g/L. These population-based ranges are not the same as optimal preventive targets. In cardiovascular prevention and longevity medicine, clinicians commonly use the following working thresholds:
        </p>
        <ul className="chk">
          <li><strong>Optimal for low-risk individuals:</strong> ApoB below 0.9 g/L.</li>
          <li><strong>Target for moderate cardiovascular risk:</strong> ApoB below 0.8 g/L.</li>
          <li><strong>Target for high cardiovascular risk</strong> (established ASCVD, diabetes, elevated Lp(a)): ApoB below 0.65-0.7 g/L.</li>
          <li><strong>Elevated:</strong> ApoB above 1.0 g/L in the context of other metabolic risk factors warrants active management.</li>
        </ul>
        <p style={paragraph}>
          The clinical target depends on overall risk profile. An ApoB of 1.1 g/L in a lean 34-year-old with no other risk factors has a different meaning than the same value in a 52-year-old with insulin resistance, hypertension, and a first-degree relative who had a heart attack at 48. Interpretation always requires clinical context which is why Veridian pairs every blood test result with a written GP report.
        </p>

        <h2 className="cg" style={sectionHeading}>Who should get a private ApoB blood test in the UK?</h2>
        <p style={paragraph}>
          ApoB is not a marker only for people already suspected of heart disease. It is particularly valuable for the significant proportion of UK adults who are metabolically dysfunctional but still have "not bad" conventional lipid results the exact group most likely to be falsely reassured by a standard NHS panel.
        </p>
        <ul className="chk">
          <li>Anyone with triglycerides above 1.5 mmol/L this is one of the earliest and most reliable signals of atherogenic dyslipidaemia.</li>
          <li>Anyone with insulin resistance, central adiposity, or elevated fasting insulin these patients are most likely to have LDL/ApoB discordance.</li>
          <li>Anyone with a personal or family history of early cardiovascular disease.</li>
          <li>Anyone with metabolic syndrome ApoB is often more informative than the standard lipid panel in this group.</li>
          <li>Anyone on statin therapy where LDL-C is now lower but residual risk may remain elevated.</li>
          <li>Anyone undergoing a comprehensive longevity review who wants a full atherogenic risk picture.</li>
        </ul>

        <h2 className="cg" style={sectionHeading}>How ApoB fits into Veridian&apos;s assessment panels</h2>
        <p style={paragraph}>
          At Veridian Clinic, ApoB is included as standard in both the Metabolic Baseline (£595) and the Longevity Panel (£795). It is interpreted alongside fasting insulin, HbA1c, triglycerides, HDL-C, liver function, full blood count, thyroid, and in the Longevity Panel lipoprotein(a) and a biological age estimate.
        </p>
        <p style={paragraph}>
          The reason ApoB is never offered as a single standalone marker at Veridian is clinical: an isolated ApoB number without fasting insulin, triglycerides, and HOMA-IR context is meaningfully harder to act on. ApoB is most useful when the metabolic drivers behind it are also understood because the treatment pathway depends on whether the elevation is primarily genetic, driven by insulin resistance, dietary, or a combination.
        </p>
        <p style={paragraph}>
          Every result from a Veridian assessment is accompanied by a GP-written report that interprets your ApoB in the context of your full panel, flags any discordance between ApoB and LDL-C, and outlines a prioritised action plan tailored to your risk pattern.
        </p>

        <ul className="chk">
          <li>ApoB included in Metabolic Baseline (£595) and Longevity Panel (£795).</li>
          <li>Nationally accredited UK laboratory processing.</li>
          <li>Three sample collection options: home kit, walk-in draw, nurse home visit.</li>
          <li>GP-written results report with personalised action plan.</li>
        </ul>

        <p style={{ fontSize: ".9rem", color: "var(--sl3)", lineHeight: 1.8, borderTop: "1px solid rgba(0,0,0,.08)", paddingTop: 16 }}>
          Related reading:{" "}
          <Link href="/blog/apob-vs-ldl" style={{ color: "var(--go)", textDecoration: "underline" }}>
            ApoB vs LDL why particle count matters more than cholesterol mass
          </Link>
          {" · "}
          <Link href="/blog/lipoprotein-a-apob-triglycerides" style={{ color: "var(--go)", textDecoration: "underline" }}>
            Lp(a), ApoB, and triglycerides the triple cardiovascular threat
          </Link>
          {" · "}
          <Link href="/blog/fast-insulin" style={{ color: "var(--go)", textDecoration: "underline" }}>
            Fasting insulin and early metabolic dysfunction
          </Link>
        </p>

        {/* Related tests */}
        <div style={{ borderTop: "1px solid rgba(0,0,0,.08)", paddingTop: 24, marginTop: 8 }}>
          <p style={{ fontSize: ".72rem", fontWeight: 700, letterSpacing: ".2em", textTransform: "uppercase", color: "var(--go)", marginBottom: 16 }}>Related Tests</p>
          <div style={{ display: "grid", gap: 10 }}>
            {[
              { href: "/blood-tests/fasting-insulin", label: "Fasting Insulin Test", note: "From £195 Energy Screen" },
              { href: "/blood-tests/lipoprotein-a", label: "Lipoprotein(a) Test", note: "From £795 Longevity Panel" },
              { href: "/blood-tests/biological-age", label: "Biological Age Test", note: "£795 Longevity Panel" },
              { href: "/blood-tests/metabolic-screen", label: "Fatigue & Energy Screen", note: "£195" },
              { href: "/blood-tests/cardiovascular-risk", label: "Cardiovascular Risk Panel", note: "£349" },
              { href: "/assessments", label: "View All Panels & Pricing", note: "Assessments →" },
            ].map((t) => (
              <Link key={t.href} href={t.href} style={{ display: "flex", justifyContent: "space-between", alignItems: "center", padding: "10px 14px", background: "var(--iv)", border: "1px solid rgba(0,0,0,.07)", textDecoration: "none" }}>
                <span style={{ fontSize: ".88rem", color: "var(--sl)", fontWeight: 500 }}>{t.label}</span>
                <span style={{ fontSize: ".78rem", color: "var(--sl3)" }}>{t.note} →</span>
              </Link>
            ))}
          </div>
        </div>
      </ClinicalArticleLayout>
    </>
  );
}
